title: Conclusions of the expert panel: importance of erlotinib as a second-line therapeutic option.
abstract: During the Experts Meeting on Lung Cancer, participants emphasized the usefulness of erlotinib as second-line therapy for lung cancer. They noted that, although there are no comparative studies, erlotinib could be as effective as docetaxel and pemetrexed in second-line therapy. Regarding the toxicity profile of each of these drugs - one of the key issues considered in the meeting - specialists pointed out how important it is to clearly identify existing differences in this issue. Each drug has different degrees of toxicity, and this information is crucial at the time of choosing the therapeutic regimen. Erlotinib treatment could be an effective option for second-line therapy.
authors.affiliation: Centro Integral de Oncología, Leandro N, Alem 460 (1832) Lomas de Zamora, Provincia de Buenos Aires, Argentina. aldoecastagnari@speedy.com.ar
authors.forename: Aldo
authors.initials: A
authors.lastname: Castagnari